

Propanc Biopharma, Inc.

10:13 21 Oct 2019

Propanc Biopharma plans to advance clinical trials on lead cancer drug PRP

Propanc Biopharma Inc (OTCMKTS:PPCB) said it is making significant progress with its lead product, cancer-fighting drug PRP, as a targeted cancer stem cell therapy.

In a statement, the company said it has completed the preclinical development of PRP and it plans to advance clinical trials in the near future.

PRP, a formulation of two pancreatic proenzymes, works by suppressing cellular pathways involved in the Epithelial to Mesenchymal Transition, a process which causes metastasis in cancer stem cells (CSCs) and ultimately can result in secondary tumors.

"Our findings from our recently published paper confirms the mechanism of action of PRP, which may prove to be [an] effective tool in the fight against metastatic cancer, the main cause of patient death for sufferers," Chief Scientific Officer Julian Kenyon said in a statement.

"By targeting CSCs, PRP is targeting the fundamental mechanism by which cancer spreads, especially after exposure to chemo or radiation, because they are non-dividing cells and are therefore resistant to standard treatments."

READ: Propanc Biopharma publishes promising study of its metastatic cancer drug in peer-reviewed medical journal

CSCs have the ability to remain dormant, the company said, which makes them radio- and chemo-resistant while remaining metastatic.

"We continue to make significant progress with our scientific understanding and development of our lead product, PRP, as a targeted cancer stem cell therapy," CEO James Nathanielsz said.

"The global metastatic cancer treatment market is predicted to reach nearly \$100 Billion over the next 5-year period, and we believe PRP has the potential to impact the way we view and treat cancer, by minimizing the potential for its return and spread in patients."

The recently published scientific paper, entitled "Pancreatic Proenzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumor engrafting," was published on August 6 in the journal Scientific Reports.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 0.0021

Market Cap: \$1.45 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: PPCB

Listing: OTCQB

52 week	High	Low
	1.75	0.0013

Sector: Pharma & Biotech

Website: www.propanc.com

Company Synopsis:

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. Together with our scientific and oncology consultants, we have developed a novel therapeutic approach based on 100 years of the scientific study of enzyme use.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.